Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Accel Entertainment enters its November earnings window with an unusual split in its signal set: an analyst lifting his price target to a fresh high even as options traders load up on protective positioning at the most defensive tilt in months.
The clearest move this week came from the Street. Macquarie's Chad Beynon raised his target on ACEL to $17, up from $16, while keeping his Outperform rating. That puts the stock roughly 55% below his target at the current price of $10.94, a gap that looks wide even accounting for the stock's 8% slide over the past month. Wells Fargo initiated coverage in August at Equal-Weight with a $14 target, and Citizens has ACEL at Market Outperform with a $15 target. The consensus remains a hold, with two hold ratings and no outright sells in the current register. The bull case rests on VGT expansion and the Dynasty Gaming acquisition as growth levers; the bear case points to Illinois market saturation, thin float, and a track record of acquisitions that have not moved the needle materially on earnings.
Options positioning has shifted sharply toward defensiveness, and that is the more pressing signal for this week. The put/call ratio jumped to 0.0604 on Tuesday, more than double its 20-day average of 0.020 and 2.3 standard deviations above that mean. For context, ACEL options have spent most of the past six weeks with a PCR near 0.003, so this week's reading is nearly at the 52-week high of 0.109. That is a meaningful uptick in demand for downside protection, even if the absolute PCR level is low by broader market standards.
Short positioning tells a much quieter story, and that contrast is worth naming. Short interest runs at 2.8% of the free float, roughly 2.3 million shares, and has drifted down about 0.6% over the past week. Borrow is nearly free at 0.88% cost to borrow, and availability is exceptionally loose at 1,300%, meaning there are roughly 13 shares available to lend for every share already borrowed. The lending market has no squeeze pressure whatsoever, and the short score of 47.9 is mid-range and drifting lower. Shorts are not driving this stock.
The ownership picture has some texture worth tracking. CEO and President Andrew Rubenstein holds just under 5% of the company and added 179,000 shares as recently as mid-September, though the 90-day net insider position across all insiders is negative at around 55,000 shares and roughly $655,000 in net value sold. The sales are mostly tax withholding and a modest 10b5-1 plan execution from the CEO in early August, rather than discretionary open-market selling. CIBC Private Wealth Group crossed the 5% Schedule 13G threshold as recently as August, moving from 0.5% to 5.7%, which is a notable accumulation on the passive register. Clairvest Group remains the dominant holder at 20.8% of shares, unchanged in the last disclosed period.
Valuation is not stretched on an earnings basis. The PE ratio is running near 10.7x and has eased about 1.2 points over the past month as the stock has pulled back. EV/EBITDA is around 5.2x. The EV/EBIT factor scores in the 78th percentile of the universe, the strongest single factor score in ACEL's profile. EPS momentum ranks in the 68th to 72nd percentile on both 30 and 90-day measures, which points to stable, if unspectacular, earnings revision trends. The next earnings print is due November 3.
What to watch heading into that November report: whether the sudden PCR spike reflects genuine hedging ahead of results or simply thin options liquidity, and whether the gap between Macquarie's $17 target and the current $10.94 price starts to close as the print approaches.
See the live data behind this article on ORTEX.
Open ACEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
